List of Excipients in Branded Drug LINCOMYCIN

Generic Drugs Containing LINCOMYCIN

Company	Ingredient	NDC	Excipient
PAI Holdings LLC dba PAI Pharma	lincomycin hydrochloride	0121-1035	BENZYL ALCOHOL
Henry Schein Inc	lincomycin hydrochloride	0404-9901	BENZYL ALCOHOL
Sagent Pharmaceuticals	lincomycin hydrochloride	25021-193	BENZYL ALCOHOL

What are the Most Frequently-Used Excipients in LINCOMYCIN?

# Of NDCs	Excipient
11	BENZYL ALCOHOL
1	WATER

Lincomycin Excipient Strategy, Formulation Patents, and Commercial Opportunities

Last updated: September 1, 2026

Lincomycin is a mature lincosamide antibiotic with no meaningful remaining composition-of-matter exclusivity in major markets. Commercial value is concentrated in formulation execution, sterile manufacturing, supply reliability, veterinary products, and differentiated delivery formats rather than in new chemical-entity protection. The strongest opportunities are preservative-free injectable products, ready-to-use infusion presentations, taste-masked oral dosage forms, and veterinary formulations with improved handling and stability.

What is the current commercial and regulatory status of lincomycin?

Lincomycin is the active ingredient in lincomycin hydrochloride products used against susceptible gram-positive infections and selected anaerobic infections. It binds the 50S ribosomal subunit and inhibits bacterial protein synthesis. Its use is constrained by the risk of severe Clostridioides difficile-associated diarrhea and colitis, reflected in FDA labeling [1].

FDA-approved dosage forms

Dosage form	Typical strength	Primary excipient issues	Commercial position
Injectable lincomycin hydrochloride	300 mg/mL or equivalent vial/ampoule presentations	pH control, preservative selection, container compatibility, dilution stability	Hospital and injectable generic market
Oral capsules	Commonly 250 mg	Moisture protection, powder flow, dissolution, capsule-shell compatibility	Mature generic market
Veterinary injectable	Product-specific	Preservatives, multidose use, animal tolerance, withdrawal periods	More active niche opportunity
Veterinary oral or feed-related products	Product-specific	Palatability, blend uniformity, stability in feed or water	Species-specific commercial opportunity

FDA labeling identifies lincomycin hydrochloride injection for serious infections caused by susceptible streptococci, pneumococci, and staphylococci when less toxic alternatives are inappropriate or ineffective [1]. Lincomycin is not positioned as a broad first-line antibiotic.

FDA approval for an old small-molecule antibiotic does not create a modern biologic-style exclusivity period. The relevant commercial barriers are abbreviated new drug application approval, drug-master-file support, sterile manufacturing capability, supply continuity, and customer qualification.

When does lincomycin lose exclusivity?

Lincomycin’s original composition-of-matter and manufacturing patent protection expired decades ago. There is no commercially meaningful active-ingredient patent barrier comparable to the patent estates surrounding recently approved antibiotics.

Exclusivity timeline

Protection category	Lincomycin position
Original compound patent	Expired
Original fermentation or manufacturing patents	Expired or commercially irrelevant
FDA new chemical entity exclusivity	Expired
Pediatric exclusivity	No current commercial significance
Orphan-drug exclusivity	Not relevant to the standard product
Biosimilar exclusivity	Not applicable
Formulation patents	Potentially available for new, non-obvious delivery systems
Method-of-use patents	Possible only for a genuinely differentiated and patentable use
Generic substitution	Available where an approved therapeutically equivalent product exists

Lincomycin is a small molecule, so biosimilar competition is not relevant. Competition occurs through generic drug applications, regulatory filings, contract manufacturing, and private-label supply agreements.

What patents protect lincomycin products today?

The active ingredient is not protected by a current foundational patent estate in the United States, Europe, or other major pharmaceutical markets. Any commercially relevant protection would need to arise from a new formulation, delivery system, manufacturing process, device, packaging configuration, or narrowly defined use.

Patentable formulation concepts

Potentially protectable subject matter includes:

1. A sterile injectable composition with a defined pH range that improves long-term stability.
2. A preservative-free multidose or unit-dose presentation with validated microbial control.
3. A ready-to-administer infusion product with defined concentration and container materials.
4. A taste-masked oral formulation that maintains dissolution and bioavailability.
5. A sustained-release oral formulation that reduces dosing frequency.
6. A veterinary formulation that improves palatability, injection-site tolerance, or withdrawal-period management.
7. A low-particulate injectable formulation with defined filtration and container-closure controls.
8. A lyophilized formulation that improves storage stability in temperature-sensitive supply chains.

A patent claim covering only the use of a conventional excipient with lincomycin would face substantial novelty and inventive-step risk. The strongest claims would link the excipient selection to a measurable technical effect, such as lower degradation, lower particulate formation, improved infusion compatibility, or improved in-use stability.

What is the Orange Book status of lincomycin?

The Orange Book status depends on the specific reference product and dosage form. Approved generic products may be listed with therapeutic-equivalence evaluations, while discontinued or inactive products can have different listing treatment. Orange Book entries should be reviewed by product number and dosage form rather than by active ingredient alone [2].

For commercial planning, the relevant questions are:

• Whether a reference-listed drug remains active.
• Whether the target product has an AB-rated generic comparator.
• Whether the proposed strength and dosage form are already approved.
• Whether the product requires a new drug application, an abbreviated new drug application, or a suitability petition.
• Whether the formulation differs in a way that affects pharmaceutical equivalence or bioequivalence.

A formulation company should not assume that an old product has an open regulatory pathway merely because its patent protection has expired. FDA product-listing status, discontinued-product status, and current reference-product availability can affect the filing strategy.

What excipients are used in lincomycin injections?

The injectable product requires the most commercially relevant excipient work. Public labeling for lincomycin hydrochloride injection identifies water for injection and pH adjustment, with some presentations using benzyl alcohol as a preservative [1,3].

Core injectable excipient functions

Function	Candidate excipient or control	Strategic issue
Vehicle	Water for injection	Must meet parenteral quality requirements
pH adjustment	Sodium hydroxide or hydrochloric acid	Controls chemical stability and injection tolerability
Preservation	Benzyl alcohol in selected multidose products	Pediatric and neonatal limitations
Tonicity	Sodium chloride or formulation-specific adjustment	Must balance tolerability and stability
Container protection	Low-extractable glass or compatible polymer	Controls adsorption, leachables, and particles
Oxygen control	Nitrogen overlay or deaeration	May reduce oxidative degradation if oxidation is a pathway
Particulate control	Filtration and process controls	Important for high-concentration sterile products

The formulation target should be established through forced-degradation studies, accelerated stability, extractables and leachables testing, particulate testing, and in-use dilution studies. A high drug concentration increases the importance of viscosity, precipitation risk, pH drift, and container compatibility.

Preservative-free opportunity

A preservative-free, single-dose lincomycin injection could address hospitals seeking to reduce benzyl alcohol exposure and simplify pediatric or neonatal medication handling. The commercial opportunity is strongest if the product provides:

• A unit-dose container.
• A validated sterile manufacturing process.
• Clear limits on reuse and in-use storage.
• Compatibility with common infusion diluents.
• Low particulate burden.
• A packaging format that reduces preparation time.

The opportunity is commercially credible but not automatically patentable. A patent would need to claim a specific composition or process that produces a demonstrated technical advantage over the labeled multidose formulation.

What formulations are protected by lincomycin patents?

No major active patent estate is known to protect the conventional lincomycin hydrochloride injection or capsule formulation. New formulation patents could still be pursued, but their scope would be narrow and vulnerable to obviousness challenges.

Injectable formulation strategy

The most practical injectable development paths are:

Ready-to-use infusion bags

A premixed bag could reduce pharmacy compounding steps and medication errors. The formulation must demonstrate stability in the selected bag material, typically polyolefin or another parenteral container, through the labeled shelf life and administration period.

Commercial advantages include lower preparation labor, easier inventory control, and reduced exposure to vial manipulation. Regulatory complexity includes container-closure qualification, sterility assurance, overfill control, and dilution equivalence.

Preservative-free ampoules or vials

Unit-dose packaging can remove the need for benzyl alcohol. The main challenge is cost per dose. A premium is more likely in hospital systems with strict preservative-reduction policies than in price-sensitive generic channels.

Lyophilized powder

Lyophilization may improve stability where the liquid product has unacceptable degradation. It also increases manufacturing cost and requires reconstitution instructions, diluent qualification, and evaluation of reconstitution time and particulate formation.

Low-volume concentrated injection

A concentrated presentation can reduce shipping and storage volume. It must maintain acceptable injection-site tolerability and dilution performance. High concentration alone is unlikely to support strong patent claims without an unexpected stability or administration benefit.

Oral formulation strategy

Lincomycin capsules are mature products. The main technical issues are powder flow, capsule filling, moisture protection, dissolution, and taste exposure after capsule rupture.

Commercially realistic oral opportunities include:

• A smaller capsule for patients with swallowing difficulty.
• A sprinkle formulation with taste masking.
• A dispersible or orally disintegrating dosage form.
• A modified-release product that reduces dosing frequency.
• A moisture-resistant package for hot and humid markets.

A modified-release product would require clinical and pharmacokinetic evidence because altered exposure could affect efficacy, tolerability, and resistance risk. The development cost may exceed the addressable market unless a defined hospital, veterinary, or geographic niche is available.

How strong is the lincomycin patent estate?

The conventional lincomycin patent estate is weak because the core molecule, standard salts, and conventional dosage forms are old. A new formulation estate could be moderate if supported by strong data and narrow claim drafting.

Patent-strength assessment

Asset type	Estimated strength	Main vulnerability
Compound patent	None of practical commercial value	Expired
Standard hydrochloride salt	Very weak	Longstanding public use
Conventional capsule	Very weak	Routine excipient and manufacturing choices
Conventional sterile injection	Weak	Prior art and predictable formulation design
Preservative-free injection	Moderate if technically differentiated	Obviousness and design-around risk
Ready-to-use infusion	Moderate	Stability and packaging claims may be narrow
Sustained-release oral product	Moderate to potentially strong	Requires proof of clinical and pharmacokinetic benefit
Veterinary palatable formulation	Moderate in a defined species	Species-specific prior art and regulatory overlap
Manufacturing process	Moderate if yield or impurity profile is improved	Process replication and enablement issues

The strongest commercial protection would likely be a coordinated package of formulation patents, process patents, trade secrets, regulatory data, and customer contracts. A single excipient patent would not be sufficient to deter generic competition.

What manufacturing and intellectual-property barriers affect lincomycin?

Manufacturing barriers are more important than active-ingredient patents. Lincomycin is produced through fermentation-derived processes, creating potential risks involving strain performance, impurity control, yield, and batch reproducibility.

Key manufacturing barriers

Fermentation and starting-material control

Manufacturers need reliable control of fermentation inputs, process parameters, impurity generation, and downstream purification. A supplier with a qualified active pharmaceutical ingredient source can have an advantage even when the API is technically off-patent.

Sterile injectable production

The injectable market requires validated aseptic processing, sterilizing filtration where appropriate, container-closure integrity testing, and control of visible and subvisible particles. These requirements limit the number of credible suppliers.

Impurity and degradation control

Formulation development should identify degradation products under heat, light, oxygen, and pH stress. The impurity profile must remain within applicable ICH and FDA expectations, with appropriate analytical methods and specifications [4,5].

Packaging compatibility

Glass, elastomer closures, and polymer infusion bags can contribute extractables, leachables, adsorption, or particulate contamination. The packaging system may become a defensible commercial differentiator if it supports longer shelf life or improved administration.

Which companies are challenging lincomycin exclusivity?

Lincomycin is primarily exposed to generic and contract-manufacturing competition rather than branded patent litigation. The competitive field includes manufacturers of injectable lincomycin hydrochloride, oral capsules, and veterinary products. Product availability varies by country and can change through discontinuations, manufacturing transfers, and supply interruptions.

Competitive landscape

Competitor type	Competitive basis	Likely customer
Injectable generic manufacturers	Price, sterile capacity, hospital contracts	Hospitals and distributors
Oral generic manufacturers	Low cost and broad distribution	Retail and institutional pharmacies
Veterinary manufacturers	Species coverage, concentration, packaging, supply	Veterinary clinics and animal-health distributors
API suppliers	Cost, quality, supply continuity	Finished-dose manufacturers
Contract manufacturers	Regulatory support and small-batch flexibility	Brand owners and private-label companies

There is limited commercial logic for a branded “me-too” lincomycin product without a clear operational advantage. A differentiated product would need to solve a measurable problem, such as preservative exposure, infusion preparation, cold-chain burden, injection volume, or veterinary administration.

What commercial opportunities exist for lincomycin excipients?

The highest-value opportunities are niche products with measurable workflow or safety benefits.

Hospital injectable opportunity

A preservative-free unit-dose injection or ready-to-use infusion could command a premium if it reduces pharmacy preparation and aligns with hospital medication-safety policies. The value proposition should be quantified through preparation time, waste reduction, error reduction, and storage requirements.

Veterinary opportunity

Veterinary lincomycin products can support better margins than human generics when they provide species-specific handling advantages. Potential product concepts include:

• Lower-volume injections for large-animal use.
• Improved injection-site tolerability.
• Palatable oral formulations.
• Stable products for farm or clinic storage.
• Packaging designed for repeated veterinary administration.
• Combination or rotation products where legally and clinically justified.

Veterinary use is subject to jurisdiction-specific approvals, residue controls, withdrawal periods, and antimicrobial stewardship requirements. FDA’s Center for Veterinary Medicine regulates animal drugs and evaluates safety, effectiveness, manufacturing, and residue considerations [6].

Emerging-market opportunity

Markets with unreliable cold-chain infrastructure may favor room-temperature-stable products, robust packaging, and longer shelf life. The regulatory route is country-specific, but formulation advantages can support tenders and distributor partnerships where price alone does not determine supply awards.

Excipient and packaging supplier opportunity

Excipient suppliers can create value through:

• Injectable-grade preservative systems.
• Low-peroxide surfactants where justified.
• Low-extractable elastomers.
• Ready-to-use infusion containers.
• Moisture-barrier capsule packaging.
• Taste-masking polymers.
• Lyophilization platforms.
• Stabilization packages supported by comparative data.

The supplier’s defensibility will depend on formulation data, regulatory documentation, global quality systems, and the ability to support customer filings.

What generic entry risks exist for lincomycin?

Generic entry risk is high for conventional dosage forms because the core product is old and formulation complexity is limited relative to newer injectable antibiotics. The main exceptions are sterile products and technically differentiated delivery systems.

Generic launch scenarios

Scenario	Probability profile	Market impact
Additional conventional capsule supplier	High	Price erosion and distributor substitution
Additional conventional injection supplier	Moderate	Hospital contract pressure
Preservative-free injection launch	Moderate	Premium niche competition
Ready-to-use infusion launch	Lower	Potential workflow-driven share gain
Veterinary reformulation	Moderate	Species- and region-specific expansion
Sustained-release oral product	Low to moderate	Requires clinical and regulatory investment

A formulation patent may delay direct copying, but generic applicants can design around narrow claims. Commercial protection is stronger when the product has a distinct presentation, established hospital protocols, and reliable supply.

What patent litigation and settlement risks apply to lincomycin?

There is no prominent current patent-litigation pattern associated with conventional lincomycin products. Paragraph IV litigation risk is therefore low for the legacy molecule and standard dosage forms, but it could arise if a new formulation receives Orange Book-listed patents.

Paragraph IV considerations

A future abbreviated new drug application could challenge listed formulation or method-of-use patents through a Paragraph IV certification. The commercial consequences would depend on:

• Whether the patent is listed for the exact dosage form.
• Whether the patent claims the formulation or only a method of use.
• Whether the reference product has regulatory exclusivity.
• Whether the patent owner files suit within the statutory period.
• Whether a 30-month stay applies.
• Whether the generic product can launch under a carve-out or after claim invalidation.

Settlement agreements would require review for launch dates, patent licenses, supply obligations, authorized-generic provisions, and restrictions on formulation or indication. No current major settlement should be assumed for legacy lincomycin without a product-specific court and FDA-record review.

How does lincomycin compare with clindamycin?

Clindamycin is the principal commercial comparator within the lincosamide class. It has broader contemporary clinical use and a larger commercial footprint, while lincomycin is generally a narrower and more mature product.

Factor	Lincomycin	Clindamycin
Class	Lincosamide	Lincosamide
Patent position	Legacy, expired	Legacy, expired
Current commercial breadth	Narrower	Broader
Oral and injectable use	Established	Established
Topical and vaginal opportunities	Limited	More developed
C. difficile concern	Material	Material
Formulation opportunity	Niche	Larger but more competitive
Veterinary opportunity	Relevant	Also relevant
Premium potential	Operational differentiation	Delivery and indication differentiation

Lincomycin can be attractive where supply is limited, a hospital requires an alternative lincosamide presentation, or a veterinary segment values a specific concentration or package. Clindamycin generally offers a larger addressable market but also more established competition.

What is the investment case for lincomycin excipient innovation?

The investment case is strongest for asset-light formulation and supply-chain strategies rather than a full new-drug program.

A commercially disciplined program would prioritize:

1. A preservative-free injectable formulation.
2. A ready-to-use or reduced-preparation hospital presentation.
3. A veterinary product with measurable administration advantages.
4. A stable oral formulation for a specific geographic or institutional market.
5. A proprietary packaging and container-closure system supported by stability data.

Development should begin with comparative formulation screening, impurity mapping, container compatibility, dilution studies, and target-product-profile analysis. The target market should be selected before expensive clinical or regulatory work begins.

Key Takeaways

• Lincomycin’s original compound and core manufacturing protections have expired.
• No biosimilar pathway applies; competition is through generic drug applications.
• Conventional capsules and injections have weak patentability and high generic-entry risk.
• Preservative-free injections, ready-to-use infusions, and veterinary products offer the clearest commercial opportunities.
• Benzyl alcohol, pH adjustment, dilution compatibility, particulate control, and packaging are central injectable formulation issues.
• A new patent estate would need to claim a specific technical effect, not merely a routine excipient substitution.
• Manufacturing quality, sterile capacity, API supply, and hospital contracting are more important than legacy patent rights.
• Lincomycin has a smaller market than clindamycin but may support targeted premium products in hospital and veterinary channels.

FAQs

Can a new excipient combination for lincomycin receive a patent?

Yes, but only if the combination is novel and non-obvious and produces a credible technical benefit, such as improved stability, reduced particulates, or improved administration performance.

Is benzyl alcohol necessary in every lincomycin injection?

No. Its use depends on the specific product design and whether the presentation is multidose or single-dose. A preservative-free product can be developed with appropriate sterile manufacturing and packaging controls.

Can lincomycin be developed as a long-acting injectable?

A long-acting injectable is technically possible but commercially demanding. It would require proof of sustained exposure, local tolerability, sterility, dose control, and clinical utility beyond conventional injection.

Are lincomycin products subject to antimicrobial stewardship restrictions?

Use may be restricted by institutional, national, or veterinary antimicrobial-stewardship policies. These restrictions can affect formulary access, tender eligibility, and commercial demand.

Is a lincomycin formulation patent likely to block all generic competition?

No. Formulation claims are usually narrow. A competitor may avoid infringement by using a different excipient system, concentration, container, process, or administration format.

References

1. U.S. Food and Drug Administration. (n.d.). Lincomycin hydrochloride injection prescribing information. DailyMed.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
3. National Library of Medicine. (n.d.). Lincomycin hydrochloride injection. DailyMed.
4. International Council for Harmonisation. (2003). Q1A(R2): Stability testing of new drug substances and products.
5. International Council for Harmonisation. (2006). Q3A(R2): Impurities in new drug substances and Q3B(R2): Impurities in new drug products.
6. U.S. Food and Drug Administration, Center for Veterinary Medicine. (n.d.). Animal drugs at FDA.